Trial Profile
A Phase 1 Study of CC-486 as a Single Agent and in Combination with Carboplatin or ABI-007 in Subjects with Relapsed or Refractory Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Anal cancer; Bladder cancer; Carcinoma; Cervical cancer; Fallopian tube cancer; Head and neck cancer; Liver metastases; Merkel cell carcinoma; Nasopharyngeal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Pelvic cancer; Peritoneal cancer; Renal cancer; Solid tumours; Squamous cell cancer; Ureteral neoplasms; Urethral cancer
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 15 May 2018 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 08 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Aug 2015 Planned End Date changed from 1 Jul 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record